EnteroMedics (NASDAQ: RSLS) and PerkinElmer (NYSE:PKI) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, earnings, dividends and profitability.
This table compares EnteroMedics and PerkinElmer’s net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
Risk & Volatility
EnteroMedics has a beta of 3.07, suggesting that its stock price is 207% more volatile than the S&P 500. Comparatively, PerkinElmer has a beta of 0.72, suggesting that its stock price is 28% less volatile than the S&P 500.
This is a summary of current ratings and recommmendations for EnteroMedics and PerkinElmer, as reported by MarketBeat.
||Strong Buy Ratings
EnteroMedics presently has a consensus price target of $11.03, indicating a potential upside of 465.64%. PerkinElmer has a consensus price target of $67.69, indicating a potential downside of 6.91%. Given EnteroMedics’ stronger consensus rating and higher possible upside, equities research analysts plainly believe EnteroMedics is more favorable than PerkinElmer.
Valuation and Earnings
This table compares EnteroMedics and PerkinElmer’s top-line revenue, earnings per share (EPS) and valuation.
||Earnings Per Share
PerkinElmer has higher revenue and earnings than EnteroMedics. EnteroMedics is trading at a lower price-to-earnings ratio than PerkinElmer, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
0.9% of EnteroMedics shares are owned by institutional investors. Comparatively, 92.1% of PerkinElmer shares are owned by institutional investors. 32.5% of EnteroMedics shares are owned by company insiders. Comparatively, 2.2% of PerkinElmer shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
PerkinElmer pays an annual dividend of $0.28 per share and has a dividend yield of 0.4%. EnteroMedics does not pay a dividend. PerkinElmer pays out 8.5% of its earnings in the form of a dividend.
PerkinElmer beats EnteroMedics on 8 of the 13 factors compared between the two stocks.
EnteroMedics Company Profile
ReShape Lifesciences Inc., formerly EnteroMedics Inc., is a medical device company. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Company’s neuroblocking technology, which is referred to as VBLOC therapy, is designed to intermittently block the vagus nerve. The Company’s initial product is the Maestro Rechargeable System, which uses VBLOC therapy to limit the expansion of the stomach, help control hunger sensations between meals, reduce the frequency and intensity of stomach contractions and produce a feeling of early and prolonged fullness. The Company’s VBLOC therapy is designed to block the gastrointestinal effects of the vagus nerve by replicating a vagotomy using high-frequency, low-energy electrical impulses to intermittently interrupt naturally occurring neural impulses on the vagus nerve between the brain and the digestive system.
PerkinElmer Company Profile
PerkinElmer, Inc. is a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment serves the environmental, food, industrial, life sciences research and laboratory services markets. It provides analytical instrumentation for the industrial market, which includes the chemical, electronics, energy, lubricant, petrochemical and polymer industries. Its products include AAnalyst, Altus, Aquamatic, Avio, AxION, Clarus, DairyGuard, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, Cell carrier and cell::explorer. The Diagnostics segment is focused on reproductive health, emerging market diagnostics and applied genomics. Its products include AutoDELFIA, BACS-on-Beads, Bioo Scientific, BoBs, Datalytix, Dexela, Dexela CMOS FPDs, Evolution, ViaCord, and Zephyr.
Receive News & Ratings for EnteroMedics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EnteroMedics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.